In Intellectual Asset Management (IAM), Fresenius Kabi Intellectual Property Chief Rachel Moodie discusses the worsening problem of patent thickets in the U.S. biosimilars market. Featured in the article is MGA’s report on patent thickets, as well as a quote from MGA’s Christy Robinson, who voiced her concern regarding the future of the biosimilars market.
This report, from Matrix Global Advisors (MGA), highlights Teva’s impact on economies in 15 of the 60 countries in which Teva operates. These 15 countries comprise 60 percent of Teva’s total global workforce and 75 percent of revenues in 2020. MGA’s detailed impact analysis estimates that, in 2020, Teva’s local purchases and payroll supported more than 249,000 jobs across these 15 countries, contributed $52 billion to economic output, and generated $11.7 billion in labor income.
The new administration is making a big push to support green energy and lower carbon emissions. But are they doing it the right way?
Debating the issue are Christy Goldfuss, senior vice president for energy and environment at the Center for American Progress, and Alex Brill, senior fellow at the American Enterprise Institute.
President Biden’s tax-and-spend infrastructure plan will reduce the competitiveness of U.S. corporations, burden working-class Americans, and discourage the type of private investment in America that fuels economic growth.
The Center for Biosimilars has announced that MGA’s recent report, “How Patent Thickets Constrain the US Biosimilars Market and Domestic Manufacturing,” was the top-read article on its website for the week of June 14, 2021.
On Thursday, The Center for Biosimilars, a sister site of The American Journal of Managed Care, published an article discussing the differences between the patent systems in the United States and Europe when it comes to biosimilars. The article featured the latest report released by MGA, and authored by Alex Brill and Christy Robinson, titled “How Patent Thickets Constrain the US Biosimilars Market and Domestic Manufacturing”:
New White Paper Identifies Patent Thickets as Barrier to US Biosimilars Market and Domestic Manufacturing
“How Patent Thickets Constrain the US Biosimilars Market and Domestic Manufacturing,” authored by Alex Brill and Christy Robinson, explains how reference biologic manufacturers create thickets of overlapping, weaker follow-on patents to keep competitors from entering the market. The paper highlights how originators have strong incentives to protect their profit streams and have found patent thickets to be an easy way to significantly extend the duration of monopolies in the US, preventing access to more affordable medicines for patients.
The Senate Finance Committee held an important subcommittee hearing this week, “Closing the Tax Gap: Lost Revenue from Noncompliance and the Role of Offshore Tax Evasion.” The “tax gap,” which is the difference between the amount of tax rightfully owed by US taxpayers and the amount of tax actually paid, is not small.
President Biden has announced two ambitious, entwined economic policy agendas: raising the corporate tax rate and other taxes on large businesses to pay for a significant increase in spending on a broadly defined set of infrastructure objectives. While the case for at least some increase in infrastructure spending is sound, the case for unwinding the corporate tax reforms enacted in 2017 is not.
In his Forbes article, Personal Finance Contributor Ted Knutson discussed Tuesday’s Senate Committee on Finance hearing that focused on climate change tax reform. During the hearing, leaders on both sides of the aisle asserted that new clean energy laws should be technology neutral, so that no one industry “wins.”
On Tuesday, American Enterprise Institute resident fellow and MGA founder and CEO Alex Brill testified before the U.S. Senate Committee on Finance. The topic of the hearing was the tax treatment of energy. Brill spoke of the criticality of a “broad, efficient, technology-neutral tax policy geared toward encouraging less energy consumption and more renewable energy production” to working toward a reduction in U.S. reliance on fossil fuels—and ensuring a reduction in CO2 emissions.
President Biden’s first signature legislative accomplishment, the American Rescue Plan Act (ARPA), is now law. Nearly $1.2 trillion in fiscal aid will pour into the economy before October, and another $700 billion will be doled out over the next four years. As one of us has written previously, $1.9 trillion is a significant underestimate of the plan’s total cost if temporary expansions of several tax credits are permanently extended. The largest of these temporary policies is the expanded child tax credit (CTC), touted by Democrats as a boon to low- and middle-income households. In addition to being costlier than the sticker price, a permanent CTC expansion, a goal expressed by many Democratic lawmakers, would have the unintended consequence of reducing employment.
Alex Brill joined i24 News’ Natasha Kirtchuk on “Global Eye” to discuss the cargo ship blocking the Suez Canal, and the trade impacts felt around the world.
On fee.org, the website for the Foundation for Economic Education, author Brad Polumbo reported on Alex Brill’s estimates of the true cost of the American Rescue Plan.
Alex Brill recently joined James Pethokoukis on AEI’s Political Economy Podcast to discuss the potential economic impacts of spending initiatives in the wake of the COVID-19 pandemic.
Have a Question?
Get In Touch
Get Our latest news
1350 Connecticut Avenue NW
Washington, DC 20036